Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -3.95% and +8.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?